InChI
1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11-;/t12-,18-;/m1./s1
InChI key
UJDQGRLTPBVSFN-TVNHLQOTSA-N
SMILES string
O=S([O-])(O)=O.OC(C1=C(C[N+]2=CC(NC(NCCN)=O)=C(N2C)N)CS[C@@]([C@@H]3NC(/C(C4=NSC(N)=N4)=N\OC(C)(C)C(O)=O)=O)([H])N1C3=O)=O
form
powder
contains
arginine as stabilizer (~50%)
antibiotic activity spectrum
Gram-negative bacteria, Gram-positive bacteria
mode of action
cell wall synthesis | interferes
storage temp.
-10 to -25°C
Quality Level
General description
Ceftolozane is a novel oxyimino-aminothiazolyl cephalosporin compound. It was formerly known as CXA-101 and FR264205. Ceftolozane is structurally similar to ceftazidime with an amino-thiadiazole ring on the 7-position side chain.
Biochem/physiol Actions
Ceftolozane is an antipseudomonal β-lactam inhibitor. It is also a PBP3 inhibitor with a higher affinity for PBP1b compared with other β-lactam inhibitors. Ceftolozane is stable in human plasma, but a low plasma protein binding (20%). It is primarily excreted through urine unchanged. Ceftolozane is a potent antibiotic against Gram-negative bacteria like P. aeruginosa, and Enterobacteriaceae.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.
Mai-Chi Hong et al.
Infection and drug resistance, 6, 215-223 (2013-12-19)
The management of infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, continues to be a significant challenge to clinicians. Ceftolozane/tazobactam is a novel antibacterial and β-lactamase-inhibitor combination that has shown appreciable activity against wild-type Enterobacteriaceae and potent activity against
Fekade B Sime et al.
Antimicrobial agents and chemotherapy, 63(10) (2019-07-31)
Evaluation of dosing regimens for critically ill patients requires pharmacokinetic data in this population. This prospective observational study aimed to describe the population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal impairment and to assess the
Jens Martens-Lobenhoffer et al.
Journal of pharmacological and toxicological methods, 103, 106692-106692 (2020-03-17)
Ceftolozane is a newer β-lactam antibiotic drug effective against gram-negative pathogens. Its pharmacokinetic parameters are dominated by the patients' kidney function. Consequently, in patients with impaired kidney function or those who are treated with different forms of renal replacement therapy
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持